CSPC Pharmaceutical Group (HKG:1093) agreed to grant an exclusive license for the development, manufacturing, and commercialization of a cancer inhibitor (SYH2039) to BeiGene Switzerland, a Friday Hong Kong bourse filing said.
Methionine Adenosyltransferase 2A inhibitors or MAT2A inhibitors are potentially effective treatments for various types of cancer. They work by disrupting the metabolic processes of cancer cells.
SYH2039 targets solid tumors with MTAP deletion mutation which is found in 15% of all cancer types including glioblastoma, pancreatic cancer, and non-small cell lung cancer.
The license also implies the same permissions for any subsequent pharmaceutical product that contains the SYH2039 compound.
Under the license agreement, the group will receive upfront payments amounting to $150 million, potential development milestone payments of up to $135 million, and commercialization milestone payments of up to $1.55 billion.
The group is also eligible for tiered royalties based on the annual net sales of the relevant products.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。